Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27390995 | 0.92 | NANP (0.38) | NANPTDP1 | |
| SCHEMBL29326731 | 0.87 | TDP1 (0.31) | TDP1 | |
| SCHEMBL29326770 | 0.87 | TDP1 (0.31) | TDP1 | |
| SCHEMBL29326768 | 0.86 | TDP1 (0.30) | TDP1 | |
| SCHEMBL29727714 | 0.84 | NANP (0.31) | NANPTDP1 | |
| SCHEMBL24630164 | 0.82 | NANP (0.38) | NANPTDP1 | |
| SCHEMBL15343918 | 0.82 | NANP (0.38) | NANPTDP1 | |
| SCHEMBL126553 | 0.82 | NANP (0.38) | NANPTDP1 | |
| SCHEMBL30946520 | 0.82 | NANP (0.38) | NANPTDP1 | |
| SCHEMBL15343657 | 0.82 | NANP (0.38) | NANPTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | FCGR3B, CD47, IL2 | NANP 1968/4885TDP1 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.